189 related articles for article (PubMed ID: 30845111)
1. The future of combination treatment with checkpoint inhibitors in melanoma.
Sullivan RJ
Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
[No Abstract] [Full Text] [Related]
2. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
3. Present results and future perspectives in optimizing chronic myeloid leukemia therapy.
Carella AM; Saglio G; Mahon XF; Mauro MJ
Haematologica; 2018 Jun; 103(6):928-930. PubMed ID: 29866888
[No Abstract] [Full Text] [Related]
4. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
6. Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Grisay G; Pierrard J; Confente C; Seront E
Curr Treat Options Oncol; 2020 Dec; 22(1):7. PubMed ID: 33269438
[TBL] [Abstract][Full Text] [Related]
7. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB
Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
[No Abstract] [Full Text] [Related]
8. NCCN Guidelines Insights: Melanoma, Version 3.2016.
Coit DG; Thompson JA; Algazi A; Andtbacka R; Bichakjian CK; Carson WE; Daniels GA; DiMaio D; Fields RC; Fleming MD; Gastman B; Gonzalez R; Guild V; Johnson D; Joseph RW; Lange JR; Martini MC; Materin MA; Olszanski AJ; Ott P; Gupta AP; Ross MI; Salama AK; Skitzki J; Swetter SM; Tanabe KK; Torres-Roca JF; Trisal V; Urist MM; McMillian N; Engh A
J Natl Compr Canc Netw; 2016 Aug; 14(8):945-58. PubMed ID: 27496110
[TBL] [Abstract][Full Text] [Related]
9. Choice of first-line therapy in metastatic melanoma.
Gibney GT; Atkins MB
Cancer; 2019 Mar; 125(5):666-669. PubMed ID: 30695110
[No Abstract] [Full Text] [Related]
10. Future directions for checkpoint inhibition in melanoma.
Hamid O
Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805
[No Abstract] [Full Text] [Related]
11. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
Rozeman EA; Dekker TJA; Haanen JBAG; Blank CU
Am J Clin Dermatol; 2018 Jun; 19(3):303-317. PubMed ID: 29164492
[TBL] [Abstract][Full Text] [Related]
12. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Mahon FX
Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
[No Abstract] [Full Text] [Related]
13. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
Hansen E; Sahasrabudhe D; Sievert L
Cancer Immunol Immunother; 2016 Jun; 65(6):765-7. PubMed ID: 27067877
[No Abstract] [Full Text] [Related]
14. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
15. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
Burger JA
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
[No Abstract] [Full Text] [Related]
16. Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.
MartÃnez-Vila C; Laguna JC; Segui E; Ruiz G; Aya Moreno F; Fernandez-Morales LM; Giner Joaquim J; Padrosa J; Fernandez L; Gaba L; Victoria I; Arance Fernandez AM
J Immunother; 2021 Jun; 44(5):204-207. PubMed ID: 33950029
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
18. Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
Gkoufa A; Gogas H; Diamantopoulos PT; Ziogas DC; Psichogiou M
J Immunother; 2020 Sep; 43(7):224-229. PubMed ID: 32554976
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary.
Morris MJ; Rumble RB; Milowsky MI
J Oncol Pract; 2018 May; 14(5):319-322. PubMed ID: 29648921
[No Abstract] [Full Text] [Related]
20. Managing Patients With Relapsed Small-Cell Lung Cancer.
Gong J; Salgia R
J Oncol Pract; 2018 Jun; 14(6):359-366. PubMed ID: 29894664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
